AMLX
insider transactionsAmylyx Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
+3.8K
3.8K buy · 0 sell
Net value · 90d
$51.3K
$51.3K in · $0 out
Sentiment · 90d
Net buying
100% buying · 0% selling
Open-market trades · 90d
1
3.8K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
24.4K sh
Own New
-
Grant·A
Director
$0
24.4K sh
Own New
-
Grant·A
Director
$0
24.4K sh
Own New
-
Grant·A
Director
$0
24.4K sh
Own New
-
Grant·A
Director
$0
24.4K sh
Own New
-
Buy·P
Director
$51.3K
3.8K sh · $13.51
Own +6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Bernhardt G Zeiher | Grant A | 24.4K | $0 |
| Jun 4, 2026 | Karen Firestone | Grant A | 24.4K | $0 |
| Jun 4, 2026 | Daphne Quimi | Grant A | 24.4K | $0 |
| Jun 4, 2026 | George M Milne JR | Grant A | 24.4K | $0 |
| Jun 4, 2026 | Paul R. Fonteyne | Grant A | 24.4K | $0 |
| May 21, 2026 | Karen Firestone | Buy P | 3.8K | $51.3K |
About AMLX insider trading
This page tracks insider transactions for Amylyx Pharmaceuticals, Inc. (AMLX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.